VANCOUVER, British Columbia--(BUSINESS WIRE)-- Zymeworks Inc (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that it will host a webcast and conference call to discuss progress on its corporate priorities and upcoming catalysts.

Webcast and Conference Call Details

Zymeworks will host a webcast and conference call on Wednesday, July 8, 2020 at 4:30pm ET (1:30pm PT).

Interested parties can access the live webcast via a link from Zymeworks’ website at http://ir.zymeworks.com/events-and-presentations or join the live call and Q&A by dialing 1-800-319-4610 for North American callers, or 1-604-638-5340 for international callers. Callers should dial in five to 10 minutes prior to the scheduled start time and ask to join the “Zymeworks call”.

A recorded replay will also be available on the website shortly after the call concludes.

About Zymeworks Inc.

Zymeworks is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks’ suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks’ lead clinical candidate, ZW25, is a novel Azymetric™ bispecific antibody currently in Phase 2 clinical development. Zymeworks’ second clinical candidate, ZW49, is a bispecific antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of ZW25 with Zymeworks’ proprietary ZymeLink™ linker-cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies. For more information, visit www.zymeworks.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200630005335/en/